SK1982003A3 - Peptides presented by cells - Google Patents

Peptides presented by cells Download PDF

Info

Publication number: SK1982003A3
Authority: SK; Slovakia
Prior art keywords: peptides; protein; cells; polypeptide; cell
Prior art date: 2000-08-03

Application number

SK198-2003A

Other languages

English (en)

Slovak (sk)

Inventor

Francis J Carr

Graham Carter

Koen Hellendoorn

Original Assignee

Merck Patent Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-03

Filing date

2001-07-26

Publication date

2003-08-05

2001-07-26 Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh

2003-08-05 Publication of SK1982003A3 publication Critical patent/SK1982003A3/sk

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 282
102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 228
210000004027 cell Anatomy 0.000 claims abstract description 182
108090000623 proteins and genes Proteins 0.000 claims abstract description 150
102000004169 proteins and genes Human genes 0.000 claims abstract description 145
238000000034 method Methods 0.000 claims abstract description 132
238000004949 mass spectrometry Methods 0.000 claims abstract description 29
230000005847 immunogenicity Effects 0.000 claims abstract description 11
230000002829 reductive effect Effects 0.000 claims abstract description 11
230000004071 biological effect Effects 0.000 claims abstract description 5
238000004458 analytical method Methods 0.000 claims description 44
229920001184 polypeptide Polymers 0.000 claims description 44
210000001744 T-lymphocyte Anatomy 0.000 claims description 37
230000027455 binding Effects 0.000 claims description 30
108091054438 MHC class II family Proteins 0.000 claims description 29
229960005486 vaccine Drugs 0.000 claims description 29
102000043131 MHC class II family Human genes 0.000 claims description 28
210000005260 human cell Anatomy 0.000 claims description 18
241000282414 Homo sapiens Species 0.000 claims description 17
102000043129 MHC class I family Human genes 0.000 claims description 17
108091054437 MHC class I family Proteins 0.000 claims description 17
238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 claims description 16
238000012360 testing method Methods 0.000 claims description 15
230000001225 therapeutic effect Effects 0.000 claims description 13
238000010561 standard procedure Methods 0.000 claims description 12
238000003556 assay Methods 0.000 claims description 9
210000004443 dendritic cell Anatomy 0.000 claims description 9
238000011161 development Methods 0.000 claims description 8
239000000203 mixture Substances 0.000 claims description 8
230000037361 pathway Effects 0.000 claims description 8
201000010099 disease Diseases 0.000 claims description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
244000005700 microbiome Species 0.000 claims description 7
210000000612 antigen-presenting cell Anatomy 0.000 claims description 6
102000036639 antigens Human genes 0.000 claims description 6
108091007433 antigens Proteins 0.000 claims description 6
238000002330 electrospray ionisation mass spectrometry Methods 0.000 claims description 6
230000002163 immunogen Effects 0.000 claims description 6
230000004048 modification Effects 0.000 claims description 6
238000012986 modification Methods 0.000 claims description 6
108091005601 modified peptides Proteins 0.000 claims description 6
238000006467 substitution reaction Methods 0.000 claims description 6
230000005856 abnormality Effects 0.000 claims description 5
239000000427 antigen Substances 0.000 claims description 5
230000015861 cell surface binding Effects 0.000 claims description 5
108010058597 HLA-DR Antigens Proteins 0.000 claims description 4
102000006354 HLA-DR Antigens Human genes 0.000 claims description 4
102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims description 4
125000000539 amino acid group Chemical group 0.000 claims description 4
230000002708 enhancing effect Effects 0.000 claims description 4
108091005804 Peptidases Proteins 0.000 claims description 3
102000035195 Peptidases Human genes 0.000 claims description 3
230000008030 elimination Effects 0.000 claims description 3
238000003379 elimination reaction Methods 0.000 claims description 3
230000003834 intracellular effect Effects 0.000 claims description 3
235000019833 protease Nutrition 0.000 claims description 3
108010010378 HLA-DP Antigens Proteins 0.000 claims description 2
102000015789 HLA-DP Antigens Human genes 0.000 claims description 2
108010062347 HLA-DQ Antigens Proteins 0.000 claims description 2
238000012217 deletion Methods 0.000 claims description 2
230000037430 deletion Effects 0.000 claims description 2
238000003780 insertion Methods 0.000 claims description 2
230000037431 insertion Effects 0.000 claims description 2
230000009467 reduction Effects 0.000 claims description 2
238000002405 diagnostic procedure Methods 0.000 abstract description 6
210000004962 mammalian cell Anatomy 0.000 abstract description 4
235000018102 proteins Nutrition 0.000 description 114
150000002500 ions Chemical class 0.000 description 18
239000000523 sample Substances 0.000 description 18
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
238000001228 spectrum Methods 0.000 description 15
101710145796 Staphylokinase Proteins 0.000 description 12
238000013459 approach Methods 0.000 description 12
238000002474 experimental method Methods 0.000 description 11
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 10
238000002360 preparation method Methods 0.000 description 9
239000011159 matrix material Substances 0.000 description 8
235000001014 amino acid Nutrition 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
238000012545 processing Methods 0.000 description 7
239000000243 solution Substances 0.000 description 7
230000028993 immune response Effects 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 6
238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 6
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 5
125000003275 alpha amino acid group Chemical group 0.000 description 5
238000000132 electrospray ionisation Methods 0.000 description 5
235000019253 formic acid Nutrition 0.000 description 5
108010093013 HLA-DR1 Antigen Proteins 0.000 description 4
241001529936 Murinae Species 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
230000006044 T cell activation Effects 0.000 description 4
150000001413 amino acids Chemical class 0.000 description 4
230000000052 comparative effect Effects 0.000 description 4
238000010828 elution Methods 0.000 description 4
210000001808 exosome Anatomy 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
238000004811 liquid chromatography Methods 0.000 description 4
239000002609 medium Substances 0.000 description 4
PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 4
108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
102000007079 Peptide Fragments Human genes 0.000 description 3
108010033276 Peptide Fragments Proteins 0.000 description 3
229920002684 Sepharose Polymers 0.000 description 3
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000013461 design Methods 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
238000000605 extraction Methods 0.000 description 3
239000012634 fragment Substances 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
230000003993 interaction Effects 0.000 description 3
238000002955 isolation Methods 0.000 description 3
238000000926 separation method Methods 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 2
102100038823 RNA-binding protein 45 Human genes 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
108091008874 T cell receptors Proteins 0.000 description 2
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
239000012491 analyte Substances 0.000 description 2
230000030741 antigen processing and presentation Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000012148 binding buffer Substances 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
238000005251 capillar electrophoresis Methods 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
238000010835 comparative analysis Methods 0.000 description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000005684 electric field Effects 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
239000007789 gas Substances 0.000 description 2
210000004408 hybridoma Anatomy 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000010189 intracellular transport Effects 0.000 description 2
125000005647 linker group Chemical group 0.000 description 2
238000001819 mass spectrum Methods 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
239000007981 phosphate-citrate buffer Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000010845 search algorithm Methods 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
PCMORTLOPMLEFB-UHFFFAOYSA-N sinapinic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 description 2
241000894007 species Species 0.000 description 2
239000007921 spray Substances 0.000 description 2
238000005211 surface analysis Methods 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
241000712461 unidentified influenza virus Species 0.000 description 2
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
BQRXMLXVGQMIBO-UHFFFAOYSA-N 1,1-bis(sulfanyl)ethanol Chemical compound CC(O)(S)S BQRXMLXVGQMIBO-UHFFFAOYSA-N 0.000 description 1
QLPHBNRMJLFRGO-YDHSSHFGSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-[6-[3-(pyridin-2-yldisulfanyl)propanoylamino]hexyl]pentanamide Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)NCCCCCCNC(=O)CCSSC1=CC=CC=N1 QLPHBNRMJLFRGO-YDHSSHFGSA-N 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
108060003393 Granulin Proteins 0.000 description 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 description 1
102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 1
108010046732 HLA-DR4 Antigen Proteins 0.000 description 1
108010039343 HLA-DRB1 Chains Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000864089 Homo sapiens HLA class II histocompatibility antigen, DP alpha 1 chain Proteins 0.000 description 1
101000930802 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 1 chain Proteins 0.000 description 1
101000968032 Homo sapiens HLA class II histocompatibility antigen, DR beta 3 chain Proteins 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
108010078049 Interferon alpha-2 Proteins 0.000 description 1
102100039350 Interferon alpha-7 Human genes 0.000 description 1
229940124862 Measles virus vaccine Drugs 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
101100126329 Mus musculus Islr2 gene Proteins 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
108700005078 Synthetic Genes Proteins 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
238000013528 artificial neural network Methods 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
239000012472 biological sample Substances 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
230000022534 cell killing Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
229960003677 chloroquine Drugs 0.000 description 1
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
229960001338 colchicine Drugs 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000000205 computational method Methods 0.000 description 1
239000003636 conditioned culture medium Substances 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
239000002619 cytotoxin Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000003795 desorption Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000012631 diagnostic technique Methods 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
230000002774 effect on peptide Effects 0.000 description 1
238000002101 electrospray ionisation tandem mass spectrometry Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
230000020764 fibrinolysis Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
238000011239 genetic vaccination Methods 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
230000002439 hemostatic effect Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000126 in silico method Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000008316 intracellular mechanism Effects 0.000 description 1
210000001821 langerhans cell Anatomy 0.000 description 1
238000001001 laser micro-dissection Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
102000035118 modified proteins Human genes 0.000 description 1
108091005573 modified proteins Proteins 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
239000013642 negative control Substances 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
239000002245 particle Substances 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
230000009145 protein modification Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
238000005173 quadrupole mass spectroscopy Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000001518 sector field mass spectrometry Methods 0.000 description 1
239000002904 solvent Substances 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000004885 tandem mass spectrometry Methods 0.000 description 1
230000032258 transport Effects 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
- G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Physics & Mathematics (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Bioinformatics & Cheminformatics (AREA)
Bioinformatics & Computational Biology (AREA)
Cell Biology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Food Science & Technology (AREA)
Microbiology (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Physics & Mathematics (AREA)
Biotechnology (AREA)
Pathology (AREA)
Spectroscopy & Molecular Physics (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Tropical Medicine & Parasitology (AREA)
Optics & Photonics (AREA)
Virology (AREA)
Toxicology (AREA)
Oncology (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Communicable Diseases (AREA)
Pharmacology & Pharmacy (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

SK198-2003A 2000-08-03 2001-07-26 Peptides presented by cells SK1982003A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0018901.9A GB0018901D0 (en)	2000-08-03	2000-08-03	Peptides presented by cells
PCT/EP2001/008625 WO2002012899A2 (en)	2000-08-03	2001-07-26	Peptides presented by cells

Publications (1)

Publication Number	Publication Date
SK1982003A3 true SK1982003A3 (en)	2003-08-05

Family

ID=9896790

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK198-2003A SK1982003A3 (en)	2000-08-03	2001-07-26	Peptides presented by cells

Country Status (20)

Country	Link
US (1)	US20030171290A1 (de)
EP (1)	EP1305343B1 (de)
JP (1)	JP2004506202A (de)
KR (1)	KR20030037272A (de)
CN (1)	CN1511164A (de)
AT (1)	ATE306498T1 (de)
AU (1)	AU2001283958A1 (de)
BR (1)	BR0112925A (de)
CA (1)	CA2417767A1 (de)
CZ (1)	CZ2003464A3 (de)
DE (1)	DE60114018T2 (de)
GB (1)	GB0018901D0 (de)
HU (1)	HUP0301581A2 (de)
MX (1)	MXPA03000901A (de)
NO (1)	NO20030495D0 (de)
PL (1)	PL358874A1 (de)
RU (1)	RU2003105806A (de)
SK (1)	SK1982003A3 (de)
WO (1)	WO2002012899A2 (de)
ZA (1)	ZA200301637B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002023202A2 (en) *	2000-09-18	2002-03-21	Genzyme Corporation	Method to identify antibody targets based on mass spectrometry (maldi-tof)
EP1406091B1 (de) *	2001-06-19	2008-02-20	Suntory Limited	Verfahren zur analyse eines in der zelle auftretenden proteins oder einer mit dem protein wechselwirkenden substanz
AU2004281634B2 (en) *	2003-09-03	2011-01-27	Dendritherapeutics, Inc.	Multiplex vaccines
DE602004030811D1 (de)	2003-10-16	2011-02-10	Micromet Ag	Multispezifische deimmunisierte cd3-bindende moleküle
EP1982176A1 (de) *	2006-01-30	2008-10-22	Dako Denmark A/S	Quantifizierung antigenspezifischer t-zellen in vollblut mit hoher geschwindigkeit mittels durchflusszytometrie
EP2361930A3 (de)	2007-03-26	2011-10-26	Dako Denmark A/S	Multimere von peptide-mhc komplexen und deren verwendung in borrelia infektionskrankheiten
EP3620465B1 (de) *	2007-07-03	2025-02-19	Dako Denmark A/S	Verbesserte verfahren zur herstellung, markierung und verwendung von mhc-multimeren
US10611818B2 (en)	2007-09-27	2020-04-07	Agilent Technologies, Inc.	MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da)	2008-02-28	2019-09-09	Dako Denmark As	MHC-multimerer til Borrelia-diagnostik og sygdom
US10722562B2 (en) *	2008-07-23	2020-07-28	Immudex Aps	Combinatorial analysis and repair
GB0817244D0 (en) *	2008-09-20	2008-10-29	Univ Cardiff	Use of a protein kinase inhibitor to detect immune cells, such as T cells
WO2010037402A1 (en)	2008-10-02	2010-04-08	Dako Denmark A/S	Molecular vaccines for infectious disease
US11992518B2 (en)	2008-10-02	2024-05-28	Agilent Technologies, Inc.	Molecular vaccines for infectious disease
JP5822841B2 (ja)	2009-11-05	2015-11-24	テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド	変異型のｋｒａｓまたはｂｒａｆ遺伝子を含むがんの治療
US20150017136A1 (en) *	2013-07-15	2015-01-15	Cellectis	Methods for engineering allogeneic and highly active t cell for immunotherapy
MX2015015638A (es) *	2013-05-13	2016-10-28	Cellectis	Metodos para diseñar celulas t altamente activas para inmunoterapia.
RU2729116C2 (ru)	2015-12-16	2020-08-04	Гритстоун Онколоджи, Инк.	Идентификация, производство и применение неоантигенов
JP2019528674A (ja) *	2016-09-30	2019-10-17	セレックスライフサイエンシズ，インコーポレーテッド	タンパク質をロードしたエキソソームを含む組成物、並びにその調製及び送達のための方法
KR20260039788A (ko)	2017-10-10	2026-03-20	시애틀 프로젝트 코포레이션	핫스팟을 이용한 신생항원 동정
CA3083097A1 (en)	2017-11-22	2019-05-31	Gritstone Oncology, Inc.	Reducing junction epitope presentation for neoantigens
US12258373B2 (en)	2018-12-17	2025-03-25	Immudex Aps	Panel comprising Borrelia MHC multimers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998052976A1 (en) *	1997-05-21	1998-11-26	Biovation Limited	Method for the production of non-immunogenic proteins
WO2000034317A2 (en) *	1998-12-08	2000-06-15	Biovation Limited	Method for reducing immunogenicity of proteins
AU4676500A (en) *	1999-04-28	2000-11-10	Northwestern University	Localization of major peptide autoepitopes for nucleosome specific t cells of systemic lupus erythematosus

2000
- 2000-08-03 GB GBGB0018901.9A patent/GB0018901D0/en not_active Ceased
2001
- 2001-07-26 AU AU2001283958A patent/AU2001283958A1/en not_active Abandoned
- 2001-07-26 DE DE60114018T patent/DE60114018T2/de not_active Expired - Lifetime
- 2001-07-26 CA CA002417767A patent/CA2417767A1/en not_active Abandoned
- 2001-07-26 AT AT01962874T patent/ATE306498T1/de not_active IP Right Cessation
- 2001-07-26 WO PCT/EP2001/008625 patent/WO2002012899A2/en not_active Ceased
- 2001-07-26 MX MXPA03000901A patent/MXPA03000901A/es unknown
- 2001-07-26 CZ CZ2003464A patent/CZ2003464A3/cs unknown
- 2001-07-26 PL PL01358874A patent/PL358874A1/xx unknown
- 2001-07-26 SK SK198-2003A patent/SK1982003A3/sk not_active Application Discontinuation
- 2001-07-26 KR KR10-2003-7001568A patent/KR20030037272A/ko not_active Withdrawn
- 2001-07-26 BR BR0112925-2A patent/BR0112925A/pt not_active IP Right Cessation
- 2001-07-26 RU RU2003105806/13A patent/RU2003105806A/ru not_active Application Discontinuation
- 2001-07-26 JP JP2002517532A patent/JP2004506202A/ja active Pending
- 2001-07-26 HU HU0301581A patent/HUP0301581A2/hu unknown
- 2001-07-26 US US10/343,443 patent/US20030171290A1/en not_active Abandoned
- 2001-07-26 EP EP01962874A patent/EP1305343B1/de not_active Expired - Lifetime
- 2001-07-26 CN CNA01813694XA patent/CN1511164A/zh active Pending
2003
- 2003-01-31 NO NO20030495A patent/NO20030495D0/no unknown
- 2003-02-27 ZA ZA200301637A patent/ZA200301637B/en unknown

Also Published As

Publication number	Publication date
DE60114018T2 (de)	2006-06-29
MXPA03000901A (es)	2003-06-24
NO20030495L (no)	2003-01-31
PL358874A1 (en)	2004-08-23
CZ2003464A3 (cs)	2003-06-18
DE60114018D1 (de)	2006-02-23
ATE306498T1 (de)	2005-10-15
HUP0301581A2 (hu)	2003-08-28
NO20030495D0 (no)	2003-01-31
US20030171290A1 (en)	2003-09-11
KR20030037272A (ko)	2003-05-12
CA2417767A1 (en)	2002-02-14
BR0112925A (pt)	2003-08-26
ZA200301637B (en)	2004-02-03
AU2001283958A1 (en)	2002-02-18
GB0018901D0 (en)	2000-09-20
WO2002012899A2 (en)	2002-02-14
CN1511164A (zh)	2004-07-07
RU2003105806A (ru)	2004-07-20
JP2004506202A (ja)	2004-02-26
EP1305343A2 (de)	2003-05-02
EP1305343B1 (de)	2005-10-12
WO2002012899A3 (en)	2002-11-07

Legal Events

Date	Code	Title	Description
2011-03-04	FC9A	Refused patent application

Publication	Publication Date	Title
SK1982003A3 (en)	2003-08-05	Peptides presented by cells
EP3729958B1 (de)	2023-05-03	Identifizierung und überwachung von monoklonalen immunglobulinen nach molekülmasse
JP2013507603A (ja)	2013-03-04	署名ペプチドおよび質量分析による混合物中の個々の組換えタンパク質の多重定量化
JP2010515020A (ja)	2010-05-06	抗体定量法
US8568993B2 (en)	2013-10-29	Detection of glycopeptides and glycoproteins for medical diagnostics
de Jong	1998	Contribution of mass spectrometry to contemporary immunology
US20190073452A1 (en)	2019-03-07	Method for determining the in vivo comparability of a biologic drug and a reference drug
EP4114851A1 (de)	2023-01-11	Proteomisches screening für krankheiten
EP3333571B1 (de)	2021-06-30	Verfahren und kit zur gleichzeitigen quantifizierung von spleissvarianten des vaskulären endothelialen wachstumsfaktors (vegf-a)
KR20230089572A (ko)	2023-06-20	조직 샘플에서 디스트로핀을 측정하는 방법
JP2023512401A (ja)	2023-03-27	全細胞グリコプロテオミクス分析のための方法
Klug et al.	2009	Characterization of MHC ligands for peptide based tumor vaccination
Karle et al.	2025	MAPPs assays for non-clinical immunogenicity risk assessment: best practices recommended by the European immunogenicity platform
Demine et al.	2003	Biochemical determination of natural tumor-associated T-cell epitopes
HK1063076A (en)	2004-12-10	Peptides presented by cells
US20040018568A1 (en)	2004-01-29	Methods for detecting deantigenized T cell epitopes and uses thereof
Wiegand	2024	Molecular epitope and affinity determination of protein-protein interactions by a combination of biosensor and mass spectrometric methods
Arjunan	2008	Mapping of coronary endothelial cell membrane proteome and comparative proteomic analysis of regulatory T cells in CD73 knockout mice
Afedi	2019	Mass Spectrometry-Based Quantitative Proteomic Analysis of Biological Fluids
Boyd	2014	Hapten-mediated contact allergy: a proteomic and immunological approach
WO2021046616A1 (en)	2021-03-18	Methods of identifying mhc-bound peptides
US20040137534A1 (en)	2004-07-15	Methods for detecting deantigenized T cell epitopes and uses thereof
Simonian	2016	Proteomics analysis of brain AVM endothelium post irradiation in pursuit of targets for AVM molecular therapy
Sherman	1995	Analysis of naturally processed MHC-bound peptides by tandem mass spectrometry
Purcell et al.	0	9 Mass Spectrometric Applications in Immunoproteomics